Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | VDR | P11473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19436459 | 0.93 | GAA (0.43) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL28268959 | 0.88 | ALDH1A1 (0.41) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL4335889 | 0.87 | CA2 (0.39) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL1980138 | 0.86 | GAA (0.43) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL68796 | 0.86 | GAA (0.43) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL23882162 | 0.85 | STAT3 (0.41) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL20602083 | 0.85 | ALDH1A1 (0.41) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL28998782 | 0.84 | ALDH1A1 (0.43) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL28300633 | 0.84 | GAA (0.42) | GAASTAT3ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL979617 | 0.84 | ALDH1A1 (0.43) | GAASTAT3ALDH1A1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | AMGEN INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250296935-A1 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase | CELLTAXIS LLC (US) | 2025-09-25 | — | — | US | disclosed |
| US-12173009-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | CELLTAXIS, LLC (US) | 2024-12-24 | — | — | US | disclosed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| US-20230250104-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| EP-4065579-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| US-20220149436-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11283107-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-03-22 | — | — | US | disclosed |
| US-11267819-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | Celltaxsis, LLC (US) | 2022-03-08 | — | — | US | disclosed |
| US-20210171529-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2021-06-10 | — | — | US | disclosed |
| US-7157488-B2 | N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | CHEN ZHAOGEN | 2006-01-12 | — | — | US | disclosed |
| US-20050267205-A1 | 2,4-dihydroxybenzoic acid derivatives | J. URIACH Y COMPANIA S.A. (ES) | 2005-12-01 | — | — | US | disclosed |
| EP-1546084-A1 | 2,4-DIHYDROXYBENZOIC ACID DERIVATIVES | J. Uriach y Compania S.A. (ES) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004009528-A1 | 2,4-DIHYDROXYBENZOIC ACID DERIVATIVES | J. Uriach Y Compañia S.A. (ES) | 2004-01-29 | — | — | WO | disclosed |
| EP-1379239-A2 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2000078724-A2 | IMIDAZOLINDERIVATIVES THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | ELI LILLY AND COMPANY (US) | 2000-12-28 | — | — | WO | disclosed |
| EP-0517041-A1 | New Cephem Compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-12-09 | — | — | EP | disclosed |
| US-4535076-A | INSECTICIDES; MITICIDES, NEMATOCIDES | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1985-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12173009-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | GAA 867/4885STAT3 4344/4885ALDH1A1 1403/4885 |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | HTR6, HTR2C, HTR1B | GAA 4200/4885STAT3 4642/4885ALDH1A1 1218/4885 |
| US-20250296935-A1 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | GAA 867/4885STAT3 4344/4885ALDH1A1 1403/4885 |
| US-11267819-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | GAA 867/4885STAT3 4344/4885ALDH1A1 1403/4885 |
| US-20230250104-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTB4R, LTC4S | GAA 867/4885STAT3 4344/4885ALDH1A1 1403/4885 |
| US-20210171529-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | SCD5, SCD, FADS2 | GAA 915/4885STAT3 4387/4885ALDH1A1 326/4885 |
| US-20050267205-A1 | 2,4-dihydroxybenzoic acid derivatives | CYP24A1, NFKBIA, PAH | GAA 435/4885STAT3 504/4885ALDH1A1 101/4885 |
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | SCD5, SCD, FADS2 | GAA 915/4885STAT3 4387/4885ALDH1A1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.